Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Drug Discovery

Background:

• The InhA enzyme, crucial for fatty acid synthesis, is a validated target for anti-tubercular drug development.
• Isoniazid (INH) resistance in *Mycobacterium tuberculosis* often arises from KatG mutations, preventing INH activation.
• This resistance mechanism limits the efficacy of traditional anti-TB drugs.

Purpose of the Study:

• To review recent developments in direct InhA inhibitors as potential anti-tubercular agents.
• To explore strategies that circumvent KatG-dependent activation for combating drug-resistant tuberculosis.
• To highlight the role of 3D structural information in designing novel InhA inhibitors.

Main Methods:

• Literature review of predominant InhA direct inhibitors.
• Analysis of structure-activity relationships for identified inhibitors.
• Examination of 3D structural data of InhA in the context of drug design.

Main Results:

• Several classes of compounds directly inhibiting InhA have been developed.
• These inhibitors show potential efficacy against strains resistant to isoniazid.
• 3D structural insights are guiding the rational design of new anti-tubercular drugs targeting InhA.

Conclusions:

• Direct InhA inhibitors represent a promising therapeutic avenue for multi-drug-resistant tuberculosis (MDR-TB).
• Targeting InhA independently of KatG activation is a viable strategy to overcome existing resistance.
• Leveraging 3D structural information is critical for the continued development of effective anti-tubercular agents.